OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Douglas A. Michels sold 25,000 shares of the company’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $22.55, for a total value of $563,750.00. Following the completion of the transaction, the chief executive officer now directly owns 743,058 shares in the company, valued at $16,755,957.90. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) opened at 22.77 on Wednesday. The company’s 50-day moving average price is $21.34 and its 200-day moving average price is $16.97. The firm has a market cap of $1.35 billion, a P/E ratio of 42.09 and a beta of 1.55. OraSure Technologies, Inc. has a 12 month low of $7.09 and a 12 month high of $22.99.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.02. The business had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.07 EPS. On average, analysts predict that OraSure Technologies, Inc. will post $0.48 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/04/orasure-technologies-inc-osur-ceo-douglas-a-michels-sells-25000-shares-of-stock.html.

Several research analysts have weighed in on OSUR shares. Canaccord Genuity increased their price objective on OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Wednesday, September 20th. Jefferies Group LLC reissued a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a research report on Tuesday, September 12th. BidaskClub downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, Stephens restated an “overweight” rating and issued a $19.00 price target (up from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. OraSure Technologies currently has a consensus rating of “Buy” and an average target price of $18.04.

Several institutional investors and hedge funds have recently bought and sold shares of OSUR. USA Financial Portformulas Corp raised its position in shares of OraSure Technologies by 31.0% in the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock valued at $978,000 after purchasing an additional 13,421 shares during the period. Advisory Services Network LLC lifted its stake in shares of OraSure Technologies by 1,419.2% during the 2nd quarter. Advisory Services Network LLC now owns 12,913 shares of the medical instruments supplier’s stock valued at $223,000 after buying an additional 12,063 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of OraSure Technologies during the 2nd quarter valued at approximately $5,119,000. Koch Industries Inc. purchased a new stake in shares of OraSure Technologies during the 2nd quarter valued at approximately $216,000. Finally, Piedmont Investment Advisors LLC purchased a new stake in shares of OraSure Technologies during the 2nd quarter valued at approximately $216,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.